期刊文献+

凯时治疗下肢动脉硬化闭塞症的临床研究 被引量:2

Clinical study of Lipo PGE1 on the treatment of lower limb artherosclerosis
暂未订购
导出
摘要 目的探讨前列腺素E1脂微球载体制剂(LipoPGE1,凯时)治疗下肢动脉硬化闭塞症疗效及安全性。方法 190例动脉硬化闭塞症患者随机分为治疗组100例和对照组90例。对照组给予PGE1粉针剂;治疗组给予凯时注射液静脉滴注。疗程均为30d。治疗前后分别检测主观症状及体征、间歇性跛行距离、踝肱指数(ABI)等变化。结果两组ABI治疗后与治疗前比较,以及两组间治疗后比较,差异有统计学意义(P<0.05)。治疗组的总有效率与对照组比较,差异有统计学意义(P<0.05)。凯时的不良反应少而轻微。结论凯时注射液治疗动脉硬化闭塞症效果显著,安全性好。 Objective To observe the therapeutic and safety of prostaglandin E1 fat microspheres carrier preparations (Lipo PGE1) in the treatment of lower limb artherosclerosis(ASO). Methods 190 cases of lower limb artherosclerosis patients were randomly divided into two groups: treatment group of 100 cases and control group of 90 cases. The control group used PGE1-CD;The treatment group used Lipo PGE1, ivdrip injection treatment based on the control group. The treatment course of two groups for 30 days .Before and after the treatment to monitor changes in indicators of subjective symptoms and signs respectively,intermittent claudi- cators, ankle- brachial index distance (ABI),(etc). Results In the ABI indication,after treatment compared with those before treatment and the comparison between the two groups after treatment the differences are significant (P〈0.05). The total effective rate of the treatment group compared with controls, the differences are significant (P〈0.05). The adverse reactions of Lipo PGE1 slightly less. Conclusion The results of Lipo PGE1 injection treatment of lower limb artherosclerosis, security in good.
机构地区 山西省人民医院
出处 《中外医疗》 2013年第2期67-67,69,共2页 China & Foreign Medical Treatment
关键词 前列腺素E1脂微球载体制剂 动脉硬化闭塞症 Prostaglandin E1 fat microspheres carrier preparations Artherosclerosis
  • 相关文献

参考文献4

  • 1王爱红,许樟荣,许永杰,陈平,王玉珍,杨乐冰.前列腺素E_1脂微球载体制剂治疗糖尿病下肢动脉病变的临床观察[J].中华老年多器官疾病杂志,2005,4(1):22-25. 被引量:62
  • 2许樟荣,敬华艚尿病足国际临床指南[M].北京:人民军医出版社,2003:45-47.
  • 3Sacks D.Position statement on the use of the ankle brachial index In the evaluation of patients with peripheral vascular disease[J].J Varselnter Radio,2002,13:353.
  • 4陈伯楠,候玉芬,周涛.周围血管病中西医诊断学[M].北京:中国中医药出版社,1999:250-253.

二级参考文献8

  • 1畅坚,许樟荣,王志强,陈平,杨丽娜.糖尿病与非糖尿病患者外周动脉病变血管造影对比研究[J].中华糖尿病杂志(1006-6187),2004,12(5):324-327. 被引量:75
  • 2[1]Ouriel K. Peripheral artery disease. Lancet , 2001, 358 :1257-1264.
  • 3[3]Diabeted drafting group. Prevalence of small and large vessel disease in diabetic patients from 14 centers. The WTO multinational study of vascular disease in diabetics. Diabetologia,1985,28(Suppl): 615-640.
  • 4[4]Jude EB, Chalmers NC, Oyibo SO, et al. Peripheral arterial disease in diabetic and nondiabetic patients - a comparison of severity and outcome. Diabetes Care, 2001,24:1433-1437.
  • 5[7]Toyata T,Hirata Y. Lipo-PGE1 ,a new lipidencapsulated preparation of prostaglandin E1 placebo and prostaglandin E1-eontrolled multi center trials in patients with diabetic neuropathy and leg ulcers. Prostaglandins, 1993,46:453.
  • 6[8]Makino H, Aoki M, Hashiya N, et al. Increase in peripheral blood flow by intravenous administration of prostaglandin E1 in patients with peripheral arterial disease, accompanied by upregulation of hepatocyte growth factor. Hypertens Res, 2004,27:85-91.
  • 7[9]Mlekusch W, Schillinger M, Sabeti S, et al. Effects of intravenous prostaglandin E1 on arterial compliance: a randomized controlled trial. Vasa,2004, 33:131-136.
  • 8潘长玉,高妍,袁申元,李光伟,王姮,陆菊明,李俊来,杨国庆,张俊清,陈铭,朱良湘,刘效慈,肖平,张学文,肖新华,李文慧,姜育新.2型糖尿病下肢血管病变发生率及相关因素调查[J].中国糖尿病杂志,2001,9(6):323-326. 被引量:510

共引文献64

同被引文献23

引证文献2

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部